Public Sector Pension Investment Board (PSP Investments)’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q2
Sell
-193,265
Closed -$734K 1454
2020
Q1
$734K Hold
193,265
0.01% 1069
2019
Q4
$984K Sell
193,265
-23,200
-11% -$123K 0.01% 1377
2019
Q3
$1.09M Buy
216,465
+29,540
+16% +$147K 0.01% 1257
2019
Q2
$1.15M Buy
186,925
+113,400
+154% +$547K 0.01% 1224
2019
Q1
$341K Hold
73,525
﹤0.01% 1418
2018
Q4
$309K Buy
73,525
+15,500
+27% +$78.9K ﹤0.01% 1467
2018
Q3
$364K Buy
58,025
+10,268
+22% +$78.9K ﹤0.01% 1405
2018
Q2
$384K Buy
47,757
+3,300
+7% +$25.2K ﹤0.01% 1273
2018
Q1
$332K Hold
44,457
﹤0.01% 1256
2017
Q4
$265K Hold
44,457
﹤0.01% 1365
2017
Q3
$327K Buy
44,457
+8,263
+23% +$52.5K ﹤0.01% 1276
2017
Q2
$246K Sell
36,194
-14,600
-29% -$108K ﹤0.01% 1211
2017
Q1
$479K Buy
+50,794
New +$507K ﹤0.01% 1109

Other funds holding PGNX

Public Sector Pension Investment Board (PSP Investments)'s PGNX Position: Q2 2020 in Review

Public Sector Pension Investment Board (PSP Investments) sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 193,265 shares — an estimated $734K sold.

Public Sector Pension Investment Board (PSP Investments) first reported a position in PGNX in Q1 2017 and held it in 13 quarters. The position peaked at $1.15M in Q2 2019. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Public Sector Pension Investment Board (PSP Investments) reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Public Sector Pension Investment Board (PSP Investments) sold 193,265 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $734K.
  • Public Sector Pension Investment Board (PSP Investments) first reported a position in Progenics Pharmaceuticals Inc in Q1 2017 and held it in 13 quarters.
  • Public Sector Pension Investment Board (PSP Investments)'s Progenics Pharmaceuticals Inc position peaked at $1.15M in Q2 2019.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Public Sector Pension Investment Board (PSP Investments)'s 13F filing for Q2 2020, filed 14 Aug 2020.